Literature DB >> 15486116

Warfarin for non-rheumatic atrial fibrillation: five year experience in a district general hospital.

Z R Yousef1, S C Tandy, V Tudor, F Jishi, R J Trent, D K Watson, R P W Cowell.   

Abstract

OBJECTIVES: To assess the long term efficacy of and risks associated with computer aided oral anticoagulation for non-rheumatic atrial fibrillation (NRAF) in a district hospital setting.
DESIGN: Retrospective, age stratified, event driven clinical database analysis.
SETTING: District general hospital. PARTICIPANTS: 739 patients receiving warfarin for NRAF between 1996 and 2001. Patients were selected from an anticoagulation database through appropriate filter settings. MAIN OUTCOME MEASURES: Anticoagulation control (international normalised ratio (INR)) and hospitalisations for bleeding complications, thromboembolic events, and stroke.
RESULTS: Over 1484 patient-years, computer assisted anticoagulation was uncontrolled in 38.3% of patients (INR < 2.0 or > 3.0). No significant differences in INR control were observed with respect to patient age (< 65, 65-75, and > 75 years), although to achieve adequate control of anticoagulation, the frequency of testing increased significantly with age. Annual risks of bleeding complications, thromboembolism, and stroke were 0.76%, 0.35%, and 0.84%, respectively. No significant differences in these events were observed between the three age groups studied. Patients who had thromboembolic events and haemorrhagic complications were significantly more likely to have been under-anticoagulated (INR < 2.0) and over-anticoagulated (INR > 3.0), respectively, at the time of their clinical event.
CONCLUSIONS: Computerised long term oral anticoagulation for NRAF in a community setting of elderly and diverse patients is safe and effective. Anticoagulation control, bleeding events, thromboembolic episodes, and stroke rates are directly comparable with those reported in major clinical trials. The authors therefore support the strategy of rate control with long term oral anticoagulation for NRAF in general clinical practice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15486116      PMCID: PMC1768526          DOI: 10.1136/hrt.2003.023325

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  17 in total

1.  Hospital episode statistics: time for clinicians to get involved?

Authors:  J G Williams; R Y Mann
Journal:  Clin Med (Lond)       Date:  2002 Jan-Feb       Impact factor: 2.659

2.  The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation.

Authors:  Daniel E Singer; Robert A Hughes; Daryl R Gress; Mary A Sheehan; Lynn B Oertel; Sue Ward Maraventano; Dyan Ryan Blewett; Bernard Rosner; J Philip Kistler
Journal:  N Engl J Med       Date:  1990-11-29       Impact factor: 91.245

3.  A comparison of rate control and rhythm control in patients with atrial fibrillation.

Authors:  D G Wyse; A L Waldo; J P DiMarco; M J Domanski; Y Rosenberg; E B Schron; J C Kellen; H L Greene; M C Mickel; J E Dalquist; S D Corley
Journal:  N Engl J Med       Date:  2002-12-05       Impact factor: 91.245

4.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.

Authors:  Isabelle C Van Gelder; Vincent E Hagens; Hans A Bosker; J Herre Kingma; Otto Kamp; Tsjerk Kingma; Salah A Said; Julius I Darmanata; Alphons J M Timmermans; Jan G P Tijssen; Harry J G M Crijns
Journal:  N Engl J Med       Date:  2002-12-05       Impact factor: 91.245

5.  Persistent atrial fibrillation: rate control or rhythm control. Rate control is not inferior to rhythm control.

Authors:  Christopher J Boos; Ranjit S More; Jorg Carlsson
Journal:  BMJ       Date:  2003-06-28

6.  Adverse drug reactions and polypharmacy in the elderly in general practice.

Authors:  L J Veehof; R E Stewart; B Meyboom-de Jong; F M Haaijer-Ruskamp
Journal:  Eur J Clin Pharmacol       Date:  1999-09       Impact factor: 2.953

7.  Computer assisted management of warfarin treatment.

Authors:  R Wilson; A H James
Journal:  Br Med J (Clin Res Ed)       Date:  1984-08-18

8.  Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.

Authors:  P Petersen; G Boysen; J Godtfredsen; E D Andersen; B Andersen
Journal:  Lancet       Date:  1989-01-28       Impact factor: 79.321

9.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.

Authors:  A S Go; E M Hylek; K A Phillips; Y Chang; L E Henault; J V Selby; D E Singer
Journal:  JAMA       Date:  2001-05-09       Impact factor: 56.272

10.  Can drug compliance in the elderly be improved?

Authors:  I Wandless; J W Davie
Journal:  Br Med J       Date:  1977-02-05
View more
  7 in total

1.  Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study.

Authors:  Margaret C Fang; Alan S Go; Elaine M Hylek; Yuchiao Chang; Lori E Henault; Nancy G Jensvold; Daniel E Singer
Journal:  J Am Geriatr Soc       Date:  2006-08       Impact factor: 5.562

2.  The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US.

Authors:  Patrick W Sullivan; Thomas W Arant; Samuel L Ellis; Heather Ulrich
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 3.  Frequency of adverse events in patients with poor anticoagulation: a meta-analysis.

Authors:  Natalie Oake; Dean A Fergusson; Alan J Forster; Carl van Walraven
Journal:  CMAJ       Date:  2007-05-22       Impact factor: 8.262

Review 4.  Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review.

Authors:  Elizabeth S Mearns; Jessica Hawthorne; Ju-Sung Song; Craig I Coleman
Journal:  BMJ Open       Date:  2014-06-20       Impact factor: 2.692

5.  Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression.

Authors:  Elizabeth S Mearns; C Michael White; Christine G Kohn; Jessica Hawthorne; Ju-Sung Song; Joy Meng; Jeff R Schein; Monika K Raut; Craig I Coleman
Journal:  Thromb J       Date:  2014-06-24

6.  Warfarin: better the devil you know.

Authors:  Marc Blockman
Journal:  Cardiovasc J Afr       Date:  2017 Nov/Dec       Impact factor: 1.167

Review 7.  Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies.

Authors:  Neil S Roskell; Miny Samuel; Herbert Noack; Brigitta U Monz
Journal:  Europace       Date:  2013-02-13       Impact factor: 5.214

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.